CD4 and neoplasm: BiTE antibodies activate both CD4+ and CD8+ T cell subsets [23], [25], [26], [27], [28]; both subsets of T cells contribute to tumor cell killing at relatively low effector T cell:target tumor cell (E:T) ratios [22], [29].